Atossa Stock Analysis

ATOS -  USA Stock  

USD 0.88  0.03  3.30%

The latest fall in stock price could raise concerns from retail investors as the firm is trading at a share price of 0.88 on 1,355,180 in volume. The company executives have failed to build on market volatilities in April. However, diversifying your overall positions with Atossa Therapeutics may protect your principal portfolio during upcoming market swings. The stock standard deviation of daily returns for 90 days investing horizon is currently 5.07. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Atossa Therapeutics partners.
Please continue to Trending Equities.
  
Refresh
The Atossa Therapeutics stock analysis report makes it easy to digest most publicly released information about Atossa Therapeutics and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Atossa Stock analysis module also helps to analyze the Atossa Therapeutics price relationship with some important fundamental indicators such as market cap and management efficiency.

Atossa Stock Analysis Notes

About 38.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.86. Some equities with similar Price to Book (P/B) outperform the market in the long run. Atossa Therapeutics recorded a loss per share of 0.31. The entity had not issued any dividends in recent years. The firm had 1:15 split on the 20th of April 2018. Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington. Atossa Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 6 people. For more info on Atossa Therapeutics please contact Steven Quay at 206 588 0256 or go to https://www.atossatherapeutics.com.

Atossa Therapeutics Quarterly Cost of Revenue

0.0

Share

Atossa Therapeutics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Atossa Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Atossa Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Atossa Therapeutics generated a negative expected return over the last 90 days
Atossa Therapeutics has high historical volatility and very poor performance
Atossa Therapeutics has some characteristics of a very speculative penny stock
Atossa Therapeutics has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 1.76 K. Net Loss for the year was (20.61 M) with loss before overhead, payroll, taxes, and interest of (36.57 K).
Atossa Therapeutics currently holds about 136.38 M in cash with (16.47 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.08, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Atossa Therapeutics has a frail financial position based on the latest SEC disclosures
Latest headline from MacroaxisInsider: Acquisition by ShuChih Chen of 50000 shares of Atossa Therapeutics subject to Rule 16b-3

Atossa Therapeutics Upcoming and Recent Events

Earnings reports are used by Atossa Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Atossa Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report30th of March 2022
Next Fiscal Quarter End31st of December 2021

Atossa Therapeutics SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Atossa Therapeutics prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Atossa Therapeutics investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Atossa Therapeutics specific information freely available to individual and institutional investors to make a timely investment decision.
9th of May 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
28th of February 2022
Financial Statements and Exhibits. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Results of Operations and Financial Condition
View
14th of February 2022
Unclassified Corporate Event
View
9th of February 2022
Unclassified Corporate Event
View
4th of February 2022
Unclassified Corporate Event
View
13th of January 2022
Unclassified Corporate Event
View
15th of November 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
6th of October 2021
Submission of Matters to a Vote of Security Holders
View

Atossa Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 121.48 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Atossa Therapeutics's market, we take the total number of its shares issued and multiply it by Atossa Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Atossa Profitablity

Atossa Therapeutics' profitability indicators refer to fundamental financial ratios that showcase Atossa Therapeutics' ability to generate income relative to its revenue or operating costs. If, let's say, Atossa Therapeutics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Atossa Therapeutics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Atossa Therapeutics' profitability requires more research than a typical breakdown of Atossa Therapeutics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2022
Return on Average Assets(0.14) (0.15) 
Return on Average Equity(0.15) (0.16) 
Return on Invested Capital(12.89) (13.91) 
Return on Sales-8.1 K-8.3 K

Management Efficiency

The entity has return on total asset (ROA) of (13.93) % which means that it has lost $13.93 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (24.93) %, meaning that it created substantial loss on money invested by shareholders. Atossa Therapeutics management efficiency ratios could be used to measure how well atossa therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 05/24/2022, Return on Average Assets is likely to drop to -0.15. In addition to that, Return on Average Equity is likely to drop to -0.16. Atossa Therapeutics Tangible Asset Value is relatively stable at the moment as compared to the past year. Atossa Therapeutics reported last year Tangible Asset Value of 141.26 Million
Last ReportedProjected for 2022
Book Value per Share 1.18  1.21 
Enterprise Value over EBIT(3.45) (3.72) 
Enterprise Value over EBITDA(3.03) (3.28) 
Price to Book Value 1.47  1.97 
Tangible Assets Book Value per Share 1.21  1.24 
Enterprise Value62.4 M67.4 M
Tangible Asset Value141.3 M152.4 M

Technical Drivers

As of the 24th of May, Atossa Therapeutics shows the risk adjusted performance of (0.1), and Mean Deviation of 3.95. Atossa Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to break down and interpolate data for nineteen technical drivers for Atossa Therapeutics, which can be compared to its rivals. Please confirm Atossa Therapeutics coefficient of variation, treynor ratio, as well as the relationship between the Treynor Ratio and semi variance to decide if Atossa Therapeutics is priced correctly, providing market reflects its regular price of 0.88 per share. Given that Atossa Therapeutics is a hitting penny stock territory we recommend to closely look at its total risk alpha.

Atossa Therapeutics Price Movement Analysis

Illegal number of arguments. The output start index for this execution was zero with a total number of output elements of zero. The Mid-point over period is an average of Atossa Therapeutics highest and lowest values attained during the given period.
.

Atossa Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Atossa Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Atossa Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Atossa Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Atossa Therapeutics Predictive Daily Indicators

Atossa Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Atossa Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Atossa Therapeutics Forecast Models

Atossa Therapeutics time-series forecasting models is one of many Atossa Therapeutics' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Atossa Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Atossa Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Atossa Therapeutics stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Atossa shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Atossa Therapeutics. By using and applying Atossa Stock analysis, traders can create a robust methodology for identifying Atossa entry and exit points for their positions.
Last ReportedProjected for 2022
EBITDA Margin(14.67) (15.83) 
Gross Margin(66.89) (68.65) 
Profit Margin(15.34) (16.55) 
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington. Atossa Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 6 people.

Current Atossa Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Atossa analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Atossa analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
7.0Strong Buy1Odds
Atossa Therapeutics current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Atossa analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Atossa stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Atossa Therapeutics, talking to its executives and customers, or listening to Atossa conference calls.
Atossa Analyst Advice Details

Atossa Stock Analysis Indicators

Atossa Therapeutics stock analysis indicators help investors evaluate how Atossa Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Atossa Therapeutics shares will generate the highest return on investment. By understating and applying Atossa Therapeutics stock analysis, traders can identify Atossa Therapeutics position entry and exit signals to maximize returns.
Quick Ratio43.97
Fifty Two Week Low0.8800
Shares Short Prior Month17.48M
Average Daily Volume Last 10 Day1.29M
Average Daily Volume In Three Month1.82M
Shares Percent Shares Out15.26%
Short Percent Of Float15.27%
Forward Price Earnings-5.05
Float Shares118.83M
Fifty Two Week High9.8000
Enterprise Value To Ebitda0.39
Fifty Day Average1.1496
Two Hundred Day Average2.0577
Please continue to Trending Equities. Note that the Atossa Therapeutics information on this page should be used as a complementary analysis to other Atossa Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.

Complementary Tools for Atossa Stock analysis

When running Atossa Therapeutics price analysis, check to measure Atossa Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atossa Therapeutics is operating at the current time. Most of Atossa Therapeutics' value examination focuses on studying past and present price action to predict the probability of Atossa Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Atossa Therapeutics' price. Additionally, you may evaluate how the addition of Atossa Therapeutics to your portfolios can decrease your overall portfolio volatility.
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Money Managers
Screen money managers from public funds and ETFs managed around the world
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Is Atossa Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Atossa Therapeutics. If investors know Atossa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Atossa Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Atossa Therapeutics is measured differently than its book value, which is the value of Atossa that is recorded on the company's balance sheet. Investors also form their own opinion of Atossa Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Atossa Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Atossa Therapeutics' market value can be influenced by many factors that don't directly affect Atossa Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Atossa Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Atossa Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Atossa Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.